GWA
DGX icon

Gratus Wealth Advisors’s Quest Diagnostics DGX Stock Holding History

Gratus Wealth Advisors’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$436K Buy
2,059
+47
+2% +$9.22K 0.06% 98
2026
Q1 		$394K Sell
2,012
-70
-3% -$13.6K 0.06% 103
2025
Q4 		$361K Buy
2,082
+51
+3% +$9.29K 0.05% 106
2025
Q3 		$387K Buy
2,031
+17
+0.8% +$3.02K 0.05% 105
2025
Q2 		$362K Buy
+2,014
New +$350K 0.05% 106

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Gratus Wealth Advisors's DGX Position: Q2 2026 in Review

Gratus Wealth Advisors increased its Quest Diagnostics (DGX) stake by 2.3% in Q2 2026, buying an estimated $9.22K and bringing the position to 2,059 shares worth $436K. The position accounts for 0.06% of the portfolio, ranked #98.

Gratus Wealth Advisors first reported a position in DGX in Q2 2025 and has held it in 5 quarters since. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Gratus Wealth Advisors held 2,059 shares of Quest Diagnostics worth $436K as of Q2 2026.
  • Gratus Wealth Advisors bought 47 Quest Diagnostics shares in Q2 2026, an estimated $9.22K.
  • Quest Diagnostics made up 0.06% of Gratus Wealth Advisors's portfolio in Q2 2026, its #98 holding.
  • Gratus Wealth Advisors first reported a position in Quest Diagnostics in Q2 2025 and has held it in 5 quarters since.
  • 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Gratus Wealth Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.